Shopping Cart 0
Cart Subtotal
AED 0

Atara Biotherapeutics Inc (ATRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

Atara Biotherapeutics Inc (Atara) is a biopharmaceutical company that develops T-cell based immunotherapies for the treatment of cancers, other autoimmune diseases, and severe viral infections. The company is evaluating its lead candidate tabelecleucel, formerly ATA129, in Phase 3 for the treatment of epstein-barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) following hematopoietic cell transplant and solid organ transplant in patients who refracted rituximab. Its pipeline also encompasses an investigational candidate in Phase 2 clinical studies for refractory CMV infection; and two Phase 1 candidates for the treatment of MS; and a Phase 1 for the treatment of residual or relapsed leukemia after HCT, and for T-cell depleted HCT for patients with relapsed or refractory multiple myeloma plasma cell leukemia (PCL). It has presence in the US, Cayman Islands, Ireland, and Switzerland. Atara is headquartered in San Francisco, California, the US.

Atara Biotherapeutics Inc (ATRA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Atara Biotherapeutics Raises USD 52 Million In Series B Financing 12

Nina Biotherapeutics Raises USD 0.9 Million In Venture Financing 14

Pinta Biotherapeutics Raises USD 6.3 Million In Venture Financing 15

Santa Maria Biotherapeutics Raises USD 6.3 Million In Venture Financing 16

Santa Maria Biotherapeutics Raises USD 18 Million In Venture Financing 17

Pinta Biotherapeutics Raises USD 18 Million In Venture Financing 18

Nina Biotherapeutics Raises USD 2.5 Million In Venture Financing 19

Atara Biotherapeutics Secures USD1.01 Million in Venture Funding from Domain Associates 20

Partnerships 21

Atara Biotherapeutics and Moffitt Cancer Center Enter into Agreement 21

Atara Biotherapeutics Enters into Agreement with Merck 22

Licensing Agreements 23

Atara Biotherapeutics Amends Licensing Agreement with QIMR Berghofer 23

Atara Biotherapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 24

Atara Biotherapeutics Enters into Licensing Agreement with Amgen 26

Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 27

Equity Offering 29

Atara Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 29

Atara Biotherapeutics Raises USD140 Million in Public Offering of Shares 31

Atara Biotherapeutics Raises USD207 Million in Public Offering of Shares 33

Atara Biotherapeutics Raises USD75 Million in Public Offering of Shares 35

Atara Biotherapeutics Raises USD63 Million in IPO 37

Atara Biotherapeutics Inc-Key Competitors 39

Atara Biotherapeutics Inc-Key Employees 40

Atara Biotherapeutics Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 43

Financial Announcements 43

Nov 06, 2018: Atara Biotherapeutics announces third quarter 2018 financial results and recent operational progress 43

Aug 01, 2018: Atara Biotherapeutics announces second quarter 2018 financial results and recent operational progress 45

May 08, 2018: Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress 48

Feb 27, 2018: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress 50

Nov 09, 2017: Atara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights 54

Aug 07, 2017: Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights 56

May 04, 2017: Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights 58

Mar 09, 2017: Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights 60

Corporate Communications 61

Sep 11, 2018: Atara Biotherapeutics names Roy Baynes as Board Director 61

Jun 07, 2018: Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer 62

May 07, 2018: Atara Biotherapeutics Appoints Dietmar Berger As Global Head Of Research And Development 63

Apr 09, 2018: Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 64

Feb 21, 2018: Atara Biotherapeutics Announces Chief Financial Officer Intention to Retire in April 2018 65

May 10, 2017: Atara Biotherapeutics appoints new SVP and global commercial head 66

Product News 67

09/11/2017: Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129 67

04/03/2017: Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer 68

Product Approvals 69

Jan 03, 2017: Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD) 69

Clinical Trials 70

Jan 12, 2018: QIMR Berghofer-developed Immunotherapy for Multiple Sclerosis gets Green Light From US FDA to Proceed with Patient Enrollment at US sites for Global Phase 1 Clinical Study 70

Jan 02, 2018: Atara Biotherapeutics Announces Initiation of Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) 71

Dec 29, 2017: Atara Biotherapeutics Announces FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel In Patients With Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) 72

Dec 11, 2017: Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder 74

Nov 01, 2017: Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers 76

Oct 25, 2017: Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190 78

Oct 19, 2017: Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis 80

Oct 16, 2017: Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis 81

Aug 22, 2017: Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer 82

Jul 31, 2017: Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis 83

May 10, 2017: Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team 84

Apr 20, 2017: Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis at the American Academy of Neurology Annual Meeting 2017 85

Mar 17, 2017: Atara Bio Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis 87

Mar 09, 2017: Atara Bio Provides Update on ATA-129 88

Appendix 89

Methodology 89

About GlobalData 89

Contact Us 89

Disclaimer 89


List Of Figure

List of Figures

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Atara Biotherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Atara Biotherapeutics Raises USD 52 Million In Series B Financing 12

Nina Biotherapeutics Raises USD 0.9 Million In Venture Financing 14

Pinta Biotherapeutics Raises USD 6.3 Million In Venture Financing 15

Santa Maria Biotherapeutics Raises USD 6.3 Million In Venture Financing 16

Santa Maria Biotherapeutics Raises USD 18 Million In Venture Financing 17

Pinta Biotherapeutics Raises USD 18 Million In Venture Financing 18

Nina Biotherapeutics Raises USD 2.5 Million In Venture Financing 19

Atara Biotherapeutics Secures USD1.01 Million in Venture Funding from Domain Associates 20

Atara Biotherapeutics and Moffitt Cancer Center Enter into Agreement 21

Atara Biotherapeutics Enters into Agreement with Merck 22

Atara Biotherapeutics Amends Licensing Agreement with QIMR Berghofer 23

Atara Biotherapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 24

Atara Biotherapeutics Enters into Licensing Agreement with Amgen 26

Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 27

Atara Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 29

Atara Biotherapeutics Raises USD140 Million in Public Offering of Shares 31

Atara Biotherapeutics Raises USD207 Million in Public Offering of Shares 33

Atara Biotherapeutics Raises USD75 Million in Public Offering of Shares 35

Atara Biotherapeutics Raises USD63 Million in IPO 37

Atara Biotherapeutics Inc, Key Competitors 39

Atara Biotherapeutics Inc, Key Employees 40

Atara Biotherapeutics Inc, Other Locations 41

Atara Biotherapeutics Inc, Subsidiaries 41

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Atara Biotherapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Atara Biotherapeutics Inc (Atara) is a biopharmaceutical company that develops T-cell based immunotherapies for the treatment of cancers, other autoimmune diseases, and severe viral infections. The company is evaluating its lead candidate tabelecleucel, formerly ATA129, in Phase 3 for the treatment of epstein-barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) following hematopoietic cell transplant and solid organ transplant in patients who refracted rituximab. Its pipeline also encompasses an investigational candidate in Phase 2 clinical studies for refractory CMV infection; and two Phase 1 candidates for the treatment of MS; and a Phase 1 for the treatment of residual or relapsed leukemia after HCT, and for T-cell depleted HCT for patients with relapsed or refractory multiple myeloma plasma cell leukemia (PCL). It has presence in the US, Cayman Islands, Ireland, and Switzerland. Atara is headquartered in San Francisco, California, the US.

Atara Biotherapeutics Inc (ATRA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Atara Biotherapeutics Raises USD 52 Million In Series B Financing 12

Nina Biotherapeutics Raises USD 0.9 Million In Venture Financing 14

Pinta Biotherapeutics Raises USD 6.3 Million In Venture Financing 15

Santa Maria Biotherapeutics Raises USD 6.3 Million In Venture Financing 16

Santa Maria Biotherapeutics Raises USD 18 Million In Venture Financing 17

Pinta Biotherapeutics Raises USD 18 Million In Venture Financing 18

Nina Biotherapeutics Raises USD 2.5 Million In Venture Financing 19

Atara Biotherapeutics Secures USD1.01 Million in Venture Funding from Domain Associates 20

Partnerships 21

Atara Biotherapeutics and Moffitt Cancer Center Enter into Agreement 21

Atara Biotherapeutics Enters into Agreement with Merck 22

Licensing Agreements 23

Atara Biotherapeutics Amends Licensing Agreement with QIMR Berghofer 23

Atara Biotherapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 24

Atara Biotherapeutics Enters into Licensing Agreement with Amgen 26

Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 27

Equity Offering 29

Atara Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 29

Atara Biotherapeutics Raises USD140 Million in Public Offering of Shares 31

Atara Biotherapeutics Raises USD207 Million in Public Offering of Shares 33

Atara Biotherapeutics Raises USD75 Million in Public Offering of Shares 35

Atara Biotherapeutics Raises USD63 Million in IPO 37

Atara Biotherapeutics Inc-Key Competitors 39

Atara Biotherapeutics Inc-Key Employees 40

Atara Biotherapeutics Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 43

Financial Announcements 43

Nov 06, 2018: Atara Biotherapeutics announces third quarter 2018 financial results and recent operational progress 43

Aug 01, 2018: Atara Biotherapeutics announces second quarter 2018 financial results and recent operational progress 45

May 08, 2018: Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress 48

Feb 27, 2018: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress 50

Nov 09, 2017: Atara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights 54

Aug 07, 2017: Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights 56

May 04, 2017: Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights 58

Mar 09, 2017: Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights 60

Corporate Communications 61

Sep 11, 2018: Atara Biotherapeutics names Roy Baynes as Board Director 61

Jun 07, 2018: Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer 62

May 07, 2018: Atara Biotherapeutics Appoints Dietmar Berger As Global Head Of Research And Development 63

Apr 09, 2018: Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 64

Feb 21, 2018: Atara Biotherapeutics Announces Chief Financial Officer Intention to Retire in April 2018 65

May 10, 2017: Atara Biotherapeutics appoints new SVP and global commercial head 66

Product News 67

09/11/2017: Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129 67

04/03/2017: Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer 68

Product Approvals 69

Jan 03, 2017: Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD) 69

Clinical Trials 70

Jan 12, 2018: QIMR Berghofer-developed Immunotherapy for Multiple Sclerosis gets Green Light From US FDA to Proceed with Patient Enrollment at US sites for Global Phase 1 Clinical Study 70

Jan 02, 2018: Atara Biotherapeutics Announces Initiation of Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) 71

Dec 29, 2017: Atara Biotherapeutics Announces FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel In Patients With Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) 72

Dec 11, 2017: Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder 74

Nov 01, 2017: Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers 76

Oct 25, 2017: Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190 78

Oct 19, 2017: Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis 80

Oct 16, 2017: Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis 81

Aug 22, 2017: Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer 82

Jul 31, 2017: Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis 83

May 10, 2017: Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team 84

Apr 20, 2017: Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis at the American Academy of Neurology Annual Meeting 2017 85

Mar 17, 2017: Atara Bio Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis 87

Mar 09, 2017: Atara Bio Provides Update on ATA-129 88

Appendix 89

Methodology 89

About GlobalData 89

Contact Us 89

Disclaimer 89


List Of Figure

List of Figures

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Atara Biotherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Atara Biotherapeutics Raises USD 52 Million In Series B Financing 12

Nina Biotherapeutics Raises USD 0.9 Million In Venture Financing 14

Pinta Biotherapeutics Raises USD 6.3 Million In Venture Financing 15

Santa Maria Biotherapeutics Raises USD 6.3 Million In Venture Financing 16

Santa Maria Biotherapeutics Raises USD 18 Million In Venture Financing 17

Pinta Biotherapeutics Raises USD 18 Million In Venture Financing 18

Nina Biotherapeutics Raises USD 2.5 Million In Venture Financing 19

Atara Biotherapeutics Secures USD1.01 Million in Venture Funding from Domain Associates 20

Atara Biotherapeutics and Moffitt Cancer Center Enter into Agreement 21

Atara Biotherapeutics Enters into Agreement with Merck 22

Atara Biotherapeutics Amends Licensing Agreement with QIMR Berghofer 23

Atara Biotherapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 24

Atara Biotherapeutics Enters into Licensing Agreement with Amgen 26

Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 27

Atara Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 29

Atara Biotherapeutics Raises USD140 Million in Public Offering of Shares 31

Atara Biotherapeutics Raises USD207 Million in Public Offering of Shares 33

Atara Biotherapeutics Raises USD75 Million in Public Offering of Shares 35

Atara Biotherapeutics Raises USD63 Million in IPO 37

Atara Biotherapeutics Inc, Key Competitors 39

Atara Biotherapeutics Inc, Key Employees 40

Atara Biotherapeutics Inc, Other Locations 41

Atara Biotherapeutics Inc, Subsidiaries 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Atara Biotherapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.